title: Ceftazidime-avibactam for the treatment of complicated urinary tract infections and complicated intra-abdominal infections.
abstract: Treatment of complicated urinary tract infections and complicated intra-abdominal infections is increasingly difficult due to the rising prevalence of multidrug-resistant Gram-negative bacteria. Ceftazidime-avibactam is a combination of the established third-generation cephalosporin ceftazidime with avibactam, a novel non-β-lactam β-lactamase inhibitor, which restores the activity of ceftazidime against many β-lactamase-producing Gram-negative bacteria, including extended-spectrum β-lactamases and Klebsiella pneumoniae carbapenemases. Clinical and nonclinical studies supporting the safety and efficacy of ceftazidime-avibactam include microbiological surveillance studies of clinically relevant pathogens, in vivo animal models of infection, pharmacokinetic/pharmacodynamic target attainment analyses, Phase I clinical pharmacology studies, and Phase II/III studies in the treatment of complicated intra-abdominal infections and complicated urinary tract infections, including patients with ceftazidime-nonsusceptible Gram-negative infections.
authors.affiliation: a 1 Forest Laboratories, Inc., a subsidiary of Allergan plc (formerly Actavis plc) , New Jersey, USA.
authors.forename: Yogesh
authors.initials: Y
authors.lastname: Mawal
authors.affiliation: b 2 Allergan plc , California, USA.
authors.forename: Ian A
authors.initials: IA
authors.lastname: Critchley
authors.affiliation: c 3 Allergan plc (formerly Actavis plc) , Jersey City, NJ, USA.
authors.forename: Todd A
authors.initials: TA
authors.lastname: Riccobene
authors.affiliation: d 4 Allergan plc (formerly Actavis plc) , California, USA.
authors.forename: Angela K
authors.initials: AK
authors.lastname: Talley
mesh_terms: D000818:Animals; D053961:Azabicyclo Compounds / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002442:Ceftazidime / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D004338:Drug Combinations; D024901:Drug Resistance, Multiple, Bacterial; D006090:Gram-Negative Bacteria / Q000187:drug effects; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy / Q000382:microbiology; D006801:Humans; D059413:Intraabdominal Infections / Q000188:drug therapy* / Q000382:microbiology; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000382:microbiology; D065093:beta-Lactamase Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D053961:Azabicyclo Compounds; D004338:Drug Combinations; C000595613:avibactam, ceftazidime drug combination; D065093:beta-Lactamase Inhibitors; D002442:Ceftazidime
keywords: avibactam; ceftazidime; complicated intra-abdominal infections; complicated urinary tract infections; multidrug resistance